Barbie Cervoni, MS, RD, CD/N, CDE, is a registered dietitian (RD) and certified diabetes care and education specialist (CDCES). She has spent most of her career counseling patients with diabetes ...
HOUSTON — In the summer of 2023, the U.S. Department of Agriculture (USDA) approved lab-grown meat. Two companies were given the OK to distribute their "cultivated meat" to restaurants and ...
FDA Approves Clobazam Add-On for Lennox Syndrome The benzodiazepine is already available in 100 other countries, marketed under different brand names. News, October 24, 2011 Orphan Drug Status for ...
Upside Foods pioneers lab-grown meat, offering humane, eco-friendly alternatives to traditional farming. The company aims to capture a share of the $277.9B U.S. meat market, attracting both ...
The US Food and Drug Administration (FDA) has approved the biosimilar ustekinumab-aekn (Selarsdi) for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis in adults and ...
The FDA has approved Alvotech’s (NASDAQ:ALVO) biosimilar of Johnson & Johnson’s (NYSE:JNJ) top-selling drug Stelara. The biosimilar, called Selarsdi, will be marketed in the US by Alvotech ...
On April 3, the FDA approved Zevtera, an antibiotic with three different uses. The medication is indicated for adults with Staphylococcus aureus bloodstream infections, including right-sided ...
Consumers could soon get a taste of cultivated quail, after Australian alternative protein firm Vow received the regulatory approval from the Singapore Food Agency (SFA) to sell their product here, ...
ImmunityBio's drug is combined with the BCG vaccine, which is mainly used against tuberculosis and for some forms of bladder cancer. Anktiva is expected to be available in the U.S. by mid-May 2024.
The FDA has granted accelerated approval to Ojemda for patients 6 months and older with relapsed or refractory pediatric low-grade glioma with a BRAF fusion or rearrangement, or BRAF V600 mutation.
The FDA has approved Roche’s Alecensa for the treatment of early stage resected non-small cell lung cancer, or NSCLC, with ALK+ mutations. Roche said that the approval makes Alecensa the first ...